LEAD CANDIDATE AND APPLICATIONS
The lead APAC therapeutic candidate has completed pre-clinical development. Aplagon is partnered with Cadila Pharmaceuticals Ltd. for the clinical development and commercialization of this APAC treatment in India. Together, the companies are pursuing selected indications where currently no optimal treatments exist.
APACs also have potential applications across a number of other therapeutic indications including the prevention of ischemic reperfusion injury.
As a priority, Aplagon is pursuing the clinical development of APACs for selected, challenging and even life-threatening indications. These include blood vessel occlusions related to vascular interventions, where currently no optimal treatments exist.
Aplagon is also exploring additional indications, including the prevention of ischemic reperfusion injury.
Aplagon has a strong IP protection for APACs.